Immunotherapy of primary moloney sarcoma-virus-induced tumors

✍ Scribed by A. Fefer

• Publisher: John Wiley and Sons
• Year: 1970
• Tongue: French
• Weight: 794 KB
• Volume: 5
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910050305

✦ Synopsis

Abstract

Adult mice inoculated with MSV develop tumors, 90% of which undergo immunologically‐mediated regression. Sublethal cyclophosphamide (CY) administered to such tumor‐bearing mice prevented regression, so that 58/60 mice died with tumors. As hosts for immunotherapy, adult BALB/c mice bearing primary tumors and given CY were injected with BALB/c spleen cells. Cumulatively, 80/85 tumors treated with cells from mice immunized with MSV completely regressed, whereas only 6/92 tumors regressed after treatment with normal or non‐specifically immunized cells, or with non‐viable immune cells. The anti‐tumor effect of CY was not essential for the immunotherapeutic effect of cells. Similar experiments were performed with allogeneic spleen cells. DBA cells were effective only if specifically pre‐immunized with MSV or BALB/c Moloney sarcoma cells. Mice treated with cells from C57BI/6 donors immunized with MSV died tumor‐free with graft‐versus‐host disease, whereas mice given non‐immunized cells died of graft‐versus‐host disease with tumor. Studies with gamma‐globulin allotype as a marker for donor cells suggested that immune cells may have to persist in the host for some time in order to be effective against the tumor. Finally, specific serotherapy was only moderately effective as compared to cellular therapy.